Although targeting STUB1 may offer a rational approach to improve the anti-tumour immunity when combined with anti-PD-1 treatment, we did not observe reversal of ICB resistance in vivo, suggesting that this type or level of pathway upregulation may not be sufficient to confer therapeutic benefit, at least in the mouse models we used. The gene discussed is STUB1; the disease is neoplasm.